Abstract
Chromodomain helicase/ATPase DNA-binding protein 1-like (CHD1L) is overexpressed and highly associated with poor prognosis in many malignancies. However, the role of CHD1L in bladder cancer (BC) has not been thoroughly elucidated. The aim of this study is to investigate the relationship of CHD1L expression with clinicopathological parameters and prognosis in BC. Immunohistochemistry was carried out to investigate the protein expression of CHD1L in 153 BC tissues and 87 adjacent noncancerous tissues. Our data found that CHD1L protein expression was significantly higher in BC tissues than in adjacent noncancerous tissues (P < 0.001). CHD1L overexpression was significantly correlated with histologic grade (P = 0.005) and tumor stage (P = 0.009). The Kaplan–Meier survival analysis revealed that survival time of patients with high CHD1L expression was significantly shorter than that with low CHD1L expression. Multivariate analysis further demonstrated that CHD1L was an independent prognostic factor for patients with BC. In conclusion, CHD1L is likely to be a valuable marker for carcinogenesis and progression of BC. It might be used as an important diagnostic and prognostic marker for BC patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29. doi:10.3322/caac.20138.
Ghoneim MA, Abdel-Latif M, el-Mekresh M, Abol-Enein H, Mosbah A, Ashamallah A, et al. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol. 2008;180:121–7.
Vishnu P, Mathew J, Tan WW. Current therapeutic strategies for invasive and metastatic bladder cancer. Onco Targets Ther. 2011;4:97–113. doi:10.2147/OTT.S22875.
Ma NF, Hu L, Fung JM, Xie D, Zheng BJ, Chen L, et al. Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma. Hepatology. 2008;47:503–10. doi:10.1002/hep.22072.
Flaus A, Martin DM, Barton GJ, Owen-Hughes T. Identification of multiple distinct Snf2 subfamilies with conserved structural motifs. Nucleic Acids Res. 2006;34:2887–905. doi:10.1093/nar/gkl295.
Eisen JA, Sweder KS, Hanawalt PC. Evolution of the SNF2 family of proteins: subfamilies with distinct sequences and functions. Nucleic Acids Res. 1995;23:2715–23.
Hyeon J, Ahn S, Park CK. CHD1L is a marker for poor prognosis of hepatocellular carcinoma after surgical resection. Korean J Pathol. 2013;47(1):9–15. doi:10.4132/KoreanJPathol.2013.47.1.9.
Li Y, Chen L, Chan TH, Liu M, Kong KL, Qiu JL, et al. SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes BC cell invasiveness and metastasis in mice. Gastroenterology. 2013;144:179–91.e4. doi:10.1053/j.gastro.2012.09.042.
Chen L, Yuan YF, Li Y, Chan TH, Zheng BJ, Huang J, et al. Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion. Gut. 2011;60:534–43. doi:10.1136/gut.2010.224071.
Chen L, Chan TH, Yuan YF, Hu L, Huang J, Ma S, et al. CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. J Clin Invest. 2010;120:1178–91. doi:10.1172/JCI40665.
He WP, Zhou J, Cai MY, Xiao XS, Liao YJ, Kung HF, et al. CHD1L protein is overexpressed in human ovarian carcinomas and is a novel predictive biomarker for patients survival. BMC Cancer. 2012;12:437. doi:10.1186/1471-2407-12-437.
Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene. 2005;24:5218–25. doi:10.1038/sj.onc.1208705.
Borden Jr LS, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol. 2005;17:275–80.
Snowdon J, Boag S, Feilotter H, Izard J, Siemens DR. A pilot study of urinary microRNA as a biomarker for urothelial cancer. Can Urol Assoc J. 2012;15:1–5. doi:10.5489/cuaj.11115.
Ru Y, Dancik GM, Theodorescu D. Biomarkers for prognosis and treatment selection in advanced bladder cancer patients. Curr Opin Urol. 2011;21:420–7. doi:10.1097/MOU.0b013e32834956d6.
Wong N, Chan A, Lee SW, Lam E, To KF, Lai PB, et al. Positional mapping for amplified DNA sequences on 1q21-q22 in hepatocellular carcinoma indicates candidate genes over-expression. J Hepatol. 2003;38:298–306.
Acknowledgments
This work was also supported by the National Natural Science Foundation of China (no. 30772278).
Conflicts of interest
None
Author information
Authors and Affiliations
Corresponding author
Additional information
Feng Tian and Feng Xu contributed equally to this work.
Rights and permissions
About this article
Cite this article
Tian, F., Xu, F., Zhang, ZY. et al. Expression of CHD1L in bladder cancer and its influence on prognosis and survival. Tumor Biol. 34, 3687–3690 (2013). https://doi.org/10.1007/s13277-013-0951-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-013-0951-4